Xinjing Zhiyuan completed a Series B financing round exceeding 200 million yuan.

36Kr learned that recently, "Xinjing Zhiyuan" announced the completion of over 200 million yuan in Series B financing. This round of financing was co-led by Xingze Capital and a well-known industrial fund, with follow-on investments from Delian Capital, Yuanhe Holdings, and Suzhou Angel Mother Fund. Existing shareholders Tonggao Capital and GEM continued to strongly support the company. Haoyue Capital served as the exclusive financial advisor for this round of financing. It is understood that the company is an innovative enterprise focusing on the development of TCR-T immune cell therapy drugs for solid tumors.